IXICO plc Further Huntington's disease contracts (8310C)
22 Octubre 2020 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 8310C
IXICO plc
22 October 2020
IXICO plc
("IXICO" or the "Company")
Further Huntington's disease contracts
Additional Huntington's disease contracts with new and existing
large pharma clients
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it has secured new
contracts in Huntington's disease (HD) clinical trials.
The new contracts include retrospective analysis of data sets
for three Natural History Studies in Huntington's disease with a
new large pharma customer and a multicentre, open-label Phase II
study in Huntington's disease with an existing large pharma
customer.
Whilst these contracts to support HD clinical trials are not to
the same scale as the GBP10.5m contract announced in April 2020,
these additional contracts reflect the strong position IXICO has as
a trusted neuroscience technology partner in this area. These
contracts do not have significant impact on management's
expectations of performance for the year but contribute to the
Company's strong order book. In addition to this, these contracts
are for early stage clinical trials and, as already demonstrated,
IXICO has a strong track record of following clinical assets
through to phase III where the contracts generate greater
revenues.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"Huntington's disease is a devastating rare neurological condition
with unmet medical needs. IXICO has worked on several HD clinical
studies since 2007 and is pleased to build further momentum in our
mission to support our clients in delivering data analytics in
these challenging areas of rare, neurodegenerative disease. Our
services will enable clients to measure the impact of the trialled
drugs with greater confidence and potentially unlock new insights
into disease progression and drug development ."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTEASEFAFPEFFA
(END) Dow Jones Newswires
October 22, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024